Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Innovation Pharmaceuticals Inc.
Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate
July 22, 2022
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
June 28, 2022
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
June 23, 2022
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology
June 15, 2022
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
March 15, 2022
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
March 07, 2022
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022
December 07, 2021
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Provides Brilacidin Program Update
November 18, 2021
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Conducting Full Data Analysis of Phase 2 Brilacidin COVID-19 Trial Results to Support Brilacidin's Potential Inclusion in Government-Sponsored COVID-19 Trials
November 12, 2021
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Announces Topline Results from Phase 2 Clinical Trial of Brilacidin for COVID-19
November 11, 2021
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Topics
Death
Tickers
IPIX
Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19
November 03, 2021
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals' COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th
October 25, 2021
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin's Broad-Spectrum Antiviral Properties
September 23, 2021
From
Innovation Pharmaceuticals Inc.
Via
AccessWire
Tickers
IPIX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit